Formycon AG (ETR:FYB)
Germany · Delayed Price · Currency is EUR | Market Cap | 418.65M |
| Revenue (ttm) | 48.07M |
| Net Income (ttm) | -165.17M |
| Shares Out | 17.66M |
| EPS (ttm) | -9.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,146 |
| Average Volume | 17,873 |
| Open | 24.10 |
| Previous Close | 24.00 |
| Day's Range | 23.60 - 24.40 |
| 52-Week Range | 19.02 - 56.00 |
| Beta | 0.58 |
| RSI | 45.05 |
| Earnings Date | Mar 26, 2026 |
About Formycon AG
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company’s pipeline includes ustekinumab used in the treatment of Crohn’s disease, ulcerative colitis... [Read more]
Financial Performance
Financial StatementsNews
EQS-DD: Formycon AG: Active Ownership Fund SICAV SIF SCS, sell
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 13.01.2026 / 01:04 CET/CEST The issuer is solely responsi...
EQS-DD: Formycon AG: Active Ownership Fund SICAV SIF SCS, Verkauf • news
EQS-News: FDA approves another interchangeable Ranibizumab Biosimilar, Nufymco – Strengthening US Presence with Zydus as Commercialization Partner
EQS-News: Formycon AG / Key word(s): Regulatory Approval/Alliance FDA approves another interchangeable Ranibizumab Biosimilar, Nufymco – Strengthening US Presence with Zydus as Commercialization Partn...
Formycon AG: Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Canada
Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a strong foundation for a successful launch of FYB206Strong early partneri...
Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Canada
Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a strong foundation for a successful launch of FYB206 Strong early partnering ...
EQS-News: Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Canada
EQS-News: Formycon AG / Key word(s): Alliance/Agreement Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Can...
Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda biosimilar candidate FYB206 for the MENA Region
PLANEGG-MARTINSRIED, Germany and AMMAN, Jordan, Dec. 4, 2025 /PRNewswire/ -- Formycon AG (FSE: FYB, Prime Standard) and MS Pharma jointly announce that they have entered into an exclusive licensin...
Formycon, MS Pharma Sign Commercialization Partnership For Keytruda Biosimilar
(RTTNews) - Formycon AG (FYB.DE) and MS Pharma have entered into an exclusive licensing and supply agreement for the commercialization of FYB206, Formycon's biosimilar candidate to Keytruda, in the Mi...
EQS-News: Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda biosimilar candidate FYB206 for the MENA Region
EQS-News: Formycon AG / Key word(s): Agreement Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda biosimilar candidate FYB206 for the MENA Region 04.12.2025 / 06:30 CET/C...
EQS-News: NTC becomes commercialization partner for Formycon’s Eylea biosimilar FYB203/Baiama in Italy
EQS-News: Formycon AG / Key word(s): Miscellaneous NTC becomes commercialization partner for Formycon’s Eylea biosimilar FYB203/Baiama in Italy 24.11.2025 / 06:30 CET/CEST The issuer is solely respons...
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy • news
EQS-News: Ranibizumab Biosimilar Epruvy launched in Germany
EQS-News: Formycon AG / Key word(s): Product Launch Ranibizumab Biosimilar Epruvy launched in Germany 20.11.2025 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement....
EQS-News: Formycon achieves key development milestone with FYB208: Biosimilar candidate for Dupixent (dupilumab) adds another growth driver to the biosimilar portfolio
EQS-News: Formycon AG / Key word(s): Miscellaneous Formycon achieves key development milestone with FYB208: Biosimilar candidate for Dupixent (dupilumab) adds another growth driver to the biosimilar p...
Formycon AG 2025 Q3 - Results - Earnings Call Presentation
2025-11-15. The following slide deck was published by Formycon AG in conjunction with their 2025 Q3 earnings call.
Positioning Barbados as the Caribbean's Life Sciences Hub
BRIDGETOWN, Barbados, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Export Barbados (BIDC) and EarlyHealth Group (EHG), headquartered in Dubai, United Arab Emirates, have signed a Letter of Intent to jointly esta...
Formycon AG (XTER:FYB) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Challenges
Formycon AG (XTER:FYB) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Challenges
Q3 2025 Formycon AG Earnings Call Transcript
Q3 2025 Formycon AG Earnings Call Transcript
Formycon AG (FYBGF) Q3 2025 Earnings Call Transcript
Formycon's Strong Partnerships Propel 2025 Growth Outlook
Formycon is forging ahead with its ambitious 2025 goals, making significant strides in biosimilar innovation and market expansion. The launch of Europe's first pre-filled syringe for a ranibizumab bio...
EQS-News: Formycon publishes nine-month results and confirms guidance – Pipeline progress and strong partnerships drive fiscal year 2025
EQS-News: Formycon AG / Key word(s): 9 Month figures/Quarterly / Interim Statement Formycon publishes nine-month results and confirms guidance – Pipeline progress and strong partnerships drive fiscal ...
EQS-News: Formycon invites to Conference Call on 2025 Nine-Month Results and announces Participation in Investor Conferences in the 4th Quarter of 2025
EQS-News: Formycon AG / Key word(s): Miscellaneous Formycon invites to Conference Call on 2025 Nine-Month Results and announces Participation in Investor Conferences in the 4th Quarter of 2025 30.10.2...
Formycon, Teva Pharma Launch FYB201/Ranivisio Biosimilar In Pre-filled Syringe In Europe
(RTTNews) - Formycon AG (FYB.F), Bioeq AG and Teva Pharmaceutical Industries Ltd. (TEVA) on Tuesday announced the launch of FYB201/Ranivisio or ranibizumab in Europe as the first Lucentis biosimilar a...
EQS-News: Formycon’s FYB201/Ranivisio sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe
EQS-News: Formycon AG / Key word(s): Market Launch/Product Launch Formycon’s FYB201/Ranivisio sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe 21.10.20...
EQS-News: Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea biosimilar FYB203 (aflibercept) for Australia and Latin America
EQS-News: Formycon AG / Key word(s): Agreement Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea biosimilar FYB203 (aflibercept) for Australia and Latin ...
EQS-AFR: Formycon AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
EQS Preliminary announcement financial reports: Formycon AG / Preliminary announcement on the disclosure of financial statements Formycon AG: Preliminary announcement of the publication of quarterly r...